DANA; A Tool to Detect Cognitive Changes in Pre-clinical and MCI Patients

达纳；

• 批准号: 10081318
• 负责人: CORINNA E LATHAN
• 金额: $ 177.75万
• 依托单位: ANTHROTRONIX, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2022-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10081318
• 关键词: Achievement; Alzheimer disease detection; Alzheimer' s Disease; Assessment tool; Award; Biological Markers; Boston; Caring; Clinic; Cognitive; Collaborations; Data; Department of Defense; Development; Diagnosis; Diagnostic; Disease; Doctor of Philosophy; Early Diagnosis; Elderly; Engineering; Ensure; Feedback; Frequencies; Goals; Health Personnel; Home environment; Impaired cognition; Impairment; Lead; Medical; Methods; Mind; Neurocognitive; Notification; Outcome; Outcome Measure; Paper; Participant; Patients; Pattern; Performance; Phase; Pilot Projects; Population; Principal Investigator; Protocol Compliance; Sampling; Self Administration; Small Business Innovation Research Grant; Technology; Testing; Time; Universities; Variant; Visit; Woman; care providers; cognitive change; cognitive function; cognitive testing; commercialization; diagnostic accuracy; digital; experimental group; experimental study; falls; improved; insight; mild cognitive impairment; neurobehavioral; neuroimaging; pre-clinical; predictive modeling; research and development; screening; temporal measurement; tool; usability

Project Summary/Abstract The goal of this proposed two phase project is to develop the Digital Automated Neurobehavioral Assessment (DANA) app into a tool that can be easily used by patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD) and can provide clinicians with meaningful data in the tracking and diagnosis of these conditions. DANA is an FDA-cleared neurocognitive assessment tool that has been previously used with similar populations and has been shown to be a valid and reliable method for screening cognitive functioning and tracking changes in cognitive functioning over time. The specific aims of the proposal are: in Phase I (1) Determine technical feasibility and diagnostic accuracy of high-frequency cognitive testing with DANA; in Phase II (2) Technical development of DANA for in-home use; and (3) Establish predictive validity of DANA for the early detection of Alzheimer’s disease. In Phase I, this project will implement a pilot study. MCI patients and normal controls will take DANA both in-clinic and at home in order to examine the feasibility of this population using DANA in the home and DANA’s ability to discriminate between healthy and impaired users. In Phase II, this project will build on the results of Phase I to technically refine the DANA tool to better fit the needs of MCI patients. The refined app will be deployed in an experiment, involving MCI patients and normal controls, that will establish the predictive validity of DANA for the early detection of Alzheimer’s disease.

项目总结/摘要 这个拟议的两阶段项目的目标是开发数字自动化 将神经行为评估（DANA）应用程序转换为患者可以轻松使用的工具 轻度认知障碍（MCI）和阿尔茨海默病（AD），并可以提供 临床医生在跟踪和诊断这些疾病的有意义的数据。Dana 是FDA批准的神经认知评估工具，以前曾用于 相似的人群，并已被证明是一种有效和可靠的方法，用于筛选 认知功能并跟踪认知功能随时间的变化。 本方案的具体目标是：第一阶段（1）确定技术可行性， DANA高频认知测试的诊断准确性; II期（2） DANA的技术发展，用于家庭使用;（3）建立预测有效性， DANA用于早期发现阿尔茨海默病。 在第一阶段，该项目将进行试点研究。MCI患者和正常对照组将 在诊所和家中服用DANA，以检查其可行性 在家中使用DANA的人群和DANA区分健康 受损的用户。 在第二阶段，该项目将以第一阶段的成果为基础，从技术上完善DANA 更好地满足MCI患者的需求。改进后的应用程序将部署在 实验，涉及MCI患者和正常对照，将建立预测 DANA用于早期检测阿尔茨海默病的有效性。